|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Current status of injectable hormonal contraception, with special reference |
| Abrego de Aguilar M; Altamirano L; Leon DA; Caridad de Fung R; Grillo AE; |
| Gonzalez JD; Canales JR; Mojica Sanchez JD; Pozuelos JL; Ramirez L |
| ADVANCES IN CONTRACEPTION. 1997 Dec;13(4):405-17. |
| The acceptability of progestogen injectables such as Depo-Provera has been impeded by bleeding irregularities. |
| Monthly injectable contraceptives (e.g., Topasel or Perlutal) combining progestogens and estrogen have the potential |
| to improve the efficacy of this method and increase continuation by creating more regular menstrual cycles. The |
| percentage of users who continue to have a clinically acceptable menstrual pattern during the first 3 months of |
| treatment is 11.7% with Depo-Provera compared with 56.7% with Cyclofem and 62.8% with Mesigyna. When bleeding |
| disturbances do occur with monthly injectables, they tend to subside as treatment progresses. Contraception |
| termination rates for side effects, most notably menstrual disturbances, have been estimated at 20% for Cyclofem |
| and 12-27% for Mesigyna at 12 months and 7.5-24.4% for Topasel at 24 months. Efficacy rates for injectables |
| approach those achieved through surgical sterilization, while their safety is similar to that of low-dose oral |
| contraceptives. (PubHealth.info Document ID: CONT2T 530-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Current status of injectable hormonal contraception, with |
| special reference to the monthly method.", is(are) Abrego de Aguilar M; Altamirano L; Leon DA; Caridad de Fung |
| R; Grillo AE; Gonzalez JD; Canales JR; Mojica Sanchez JD; Pozuelos JL; Ramirez L. The source of this article is |
| "ADVANCES IN CONTRACEPTION. 1997 Dec;13(4):405-17.". This article was published in 1997 in English |
| language(s). (PubHealth.info® Document ID: CONT2T 530-06. All rights reserved with PubHealth.info) PIN: 5530 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |